Vielen Dank für Ihre Anfrage.
Wir werden Sie innerhalb weniger Werktage kontaktieren.
(Geschäftseinheit Performance Materials, Sales Support Team)
Gebäude AIA Central, Ebene 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesien
+62 21 2988 8557
Erfolg! Ihre Anfrage wurde an unser Vertriebsteam übermittelt.
Etwas ist schiefgelaufen! Bitte versuchen Sie es später erneut.
Wir haben 23 Elemente gefunden.
| Kontaktdaten des Antragstellers | |
| Vollständiger Name | |
| Unternehmen | |
| Position | |
| Telefonnummer | |
| Geschäftliche E-Mail-Adresse | |
| Lieferadresse | |
Thank you. Your request has been sent.
Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Urapidil Base is a white crystalline powder. When dissolved, it forms a clear, colorless solution that is free of particles.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Benserazide Hydrochloride, offered under REFARMED CHEMICALS—a subsidiary of the DKSH Group—is an essential pharmaceutical ingredient tailored for the robust demands of the medical industry. Specifically formulated for the management of Parkinson’s disease, Benserazide Hydrochloride serves as a monoamine oxidase B (MAO-B) inhibitor. When synergistically combined with levodopa, it not only amplifies the efficacy of the treatment but also mitigates associated side effects such as nausea, enhancing the quality of life for patients suffering from this neurodegenerative condition. Our Benserazide Hydrochloride emerges as a white to off-white crystalline powder, a testament to its purity and quality. The compound exhibits admirable water solubility, ensuring ease of formulation and bioavailability. Its molecular identity, C10H14N2O3·HCl, with a molecular weight of 234.7 g/mol, aligns with rigorous pharmaceutical prerequisites. Our product delivers through a strict adherence to quality with an assay value ranging from 98.5% to 101.0%, guaranteeing a high-caliber substance with minimal impurity content. REFARMED CHEMICALS prioritizes safety and compliance, validating Benserazide Hydrochloride's authenticity with the IR and Chlorides test among others, and acknowledges the product’s conscientious solubility in water and minimal solubility in anhydrous ethanol. We maintain stringent control on residual solvents, ensuring ethanol levels remain below 5000 ppm and methanol below 3000 ppm. Administered orally, this pharmaceutical agent's dosage is contingent upon individual patient needs and medical recommendations, subject to professional healthcare guidance. Despite its profound benefits, it should be noted that Benserazide Hydrochloride is contraindicated for patients with severe hepatic or renal impairments and requires cautious use in patients with a history of cardiovascular diseases, orthostatic hypotension, or psychiatric conditions. Interaction with opioids and antidepressants necessitates careful management. Upholding the highest standards, our product is compliant with Good Manufacturing Practice (GMP) and holds the Certificate of Suitability (CEP)—a rigorous certification ensuring consistency in high-quality production for our corporate customers. With REFARMED CHEMICALS, you are guaranteed a product that not only addresses the therapeutic needs but also embodies the precision and reliability sought after in the pharmaceutical industry.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Refarmed Chemicals takes pride in providing the pharmaceutical industry with high-quality Ticlopidine Hydrochloride, an essential antiplatelet medication used to prevent strokes and other significant blood clots in patients who have experienced a stroke or transient ischemic attack (TIA). Manufactured under stringent GMP certification, our Ticlopidine Hydrochloride is presented in tablet form, with a strength of 250 mg ensuring consistent dosing and efficacy. Our Ticlopidine Hydrochloride acts by hindering platelet function, thereby diminishing the aggregation essential to blood clot formation. This preventive approach serves as a critical intervention in the management of clot-related disorders, significantly improving patient outcomes. Physicians typically recommend a starting dose of 250 mg administered twice daily, emphasizing that food intake during administration reduces gastrointestinal discomfort. Monitoring patient response allows for personalized treatment adjustments to optimize therapeutic benefits while considering safety profiles. As with all pharmaceuticals, we duly note possible side effects, ranging from mild gastrointestinal issues to less common, yet more severe reactions like neutropenia or liver impairment. This necessitates caution in prescribing to populations with liver disease, a history of bleeding disorders, or inflammatory bowel disease. Continuous patient monitoring and drug interaction vigilance are paramount, especially concerning commonly used medications such as aspirin and warfarin. Compliant storage conditions entail keeping the Ticlopidine Hydrochloride tablets at room temperature (15°C to 30°C), shielded from light and moisture to maintain product integrity. Ticlopidine Hydrochloride is supplied as a generic medication, ensuring affordability without compromising quality. Embracing our commitment to patient safety and treatment adherence, we underline the significance of medical guidance before initiating or discontinuing use, with particular respect to special populations like pregnant or breastfeeding women. Rest assured, our partnership with the DKSH Group underlines a shared vision for growth and delivery of quality healthcare solutions that spans across Asia and beyond, cementing our position as a trusted supplier in the pharmaceutical landscape.
Products still subject to third-party patent protection might be available solely for R&D purposes.